USPatent applicationPatented

Soy hydrolysate based nutritional formulations

Granted 26 Oct 2004 · 3 office actions

Life of the application

16 dated events
⤢ drag to zoom20022004200620082010201220142016201820202022ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

Infant formulas and methods of providing nutrition to an infant are provided. The formula includes soy hydrolysate and other nutrients.

Description

3 parts
›BACKGROUND OF THE INVENTION

The present invention relates generally to products for providing nutritional support. More specifically, the present invention relates to infant formulas and other specialized nutritional supplements.

It is of course known to provide enteral nutrition to an individual. Such nutrition can be provided to either afford the complete nutrition requirements to the individual or as a supplement. In a similar vein, these products can either be directed to the population in general or individuals having special requirements. For example, due to disease states or other abnormalities, individuals may not be able to tolerate certain components that may be typical of most nutritional formulations.

One type of enteral nutrition is infant formulas. Infant formulas are designed to provide nutritional support to pre-term, full-term, and post-term babies. Typically, infant formulas are directed to individuals under the age of 12 months. These formulas are either designed as a substitute for or a supplement to human breast milk. Such formulations can provide the total nutritional support for an infant or they can be used to supplement an infant's diet.

Similar to the adult population, some infants are allergic to milk-based products. For example, a number of individuals have an intolerance to regular milk formulas. This is typically due to the proteins and/or lactose in the regular milk formulas. It is therefore known to provide infant formulas based on soy proteins; soy can be used as a substitute for milk.

Additionally, infants do not have fully developed digestive systems. Certain nutritional components, for example, protein, may be difficult for infants to digest during their early development.

›SUMMARY OF THE INVENTION

The present invention provides improved nutritional formulations. In a preferred embodiment, the present invention provides an infant formula that is preferably lactose free as well as is designed to be more easily digested by infants.

To this end, in an embodiment, the present invention provides an infant formula that is lactose free comprising hydrolyzed soy protein isolate.

In an embodiment, the soy hydrolysate isolate has a degree of hydrolysis of approximately 4 to about 10%.

In an embodiment, a stabilizer system is provided based on rice starch.

In an embodiment, a stabilizer system is provided based on corn starch.

In an embodiment, the soy hydrolysate isolate comprises not less than 50% by weight of the protein of the formula.

In an embodiment, based on a ready-to-use basis, the formula includes approximately 0.5 to about 5% by weight protein.

In an embodiment based on a ready-to-use basis: the formula includes approximately 0.5% to about 5% by weight protein; approximately 1% to about 10% carbohydrate; and approximately 1% to about 10% fat.

In another embodiment, the present invention provides an infant formula including: a protein source that provides approximately 0.5 to about 10% based on weight of the formula and includes soy hydrolysate isolate; a carbohydrate source; a fat source; a stabilizer system; and vitamins and minerals.

Additionally, in an embodiment, the present invention provides a method of providing an infant formula that is lactose free and more easily digested by an infant than at least some other lactose free infant formulas comprising the steps of using as a protein source soy hydrolysate.

An advantage of the present invention is to provide an improved infant formula.

Another advantage of the present invention is to provide an improved infant formula for infants that is easier to digest.

Still further, an advantage of the present invention is to provide a lactose-free infant formula.

Furthermore, an advantage of the present invention is to provide an infant formula that functions as a comfort product.

Moreover, an advantage of the present invention is to provide an enteral formulation that is more easily digested.

A further advantage of the present invention is to provide a method for providing nutrition to an individual having lactose intolerance.

Additional features and advantages of the present invention will be described in and apparent from the detailed description of the invention.

›DETAILED DESCRIPTION OF THE INVENTION

As noted above, in the preferred embodiment set forth below, the present invention provides improved infant formulas and methods for providing nutrition to infants. However, it should be noted, the present invention can be used to construct other dietary supplements for providing enteral nutrition to other individuals requiring lactose free and protein rich supplements that are easy to digest, e.g., adults.

Pursuant to an embodiment of the present invention an infant formula is provided that is lactose free. Thus, the formula can be provided to infants having an intolerance to regular milk formulas. In addition, the formula is designed to provide more easily digestible proteins. Thus, the formula can be used with infants, or other individuals that may have difficulties digesting proteins. For example, the formula can be used with infants that may be fussy due to an intolerance to regular soy protein formulas.

The present invention provides a soy hydrolysate based infant formula. It has been discovered that by providing hydrolyzed soy that a soy-based formula can be provided that is more easily digested and better tolerated and may have at least reduced allergenicity potential.

If desired, soy can comprise all of the protein source of the product. In an embodiment, soy comprises approximately 25% to about 75% by weight of the protein source of the product. In an embodiment, soy comprises up to approximately 50% by weight of the protein component of the formula. In an embodiment, the soy comprises 30% by weight of the total protein of the formula.

A number of soy hydrolysates can be utilized. Preferably, the soy is hydrolyzed to a moderate degree. For example, the hydrolysis, as measured by degree of hydrolysis, is preferably in the range of approximately 4 to about 10% and most preferably approximately 5 to about 8%. With a hydrolysis of, for example, 4 to 7%, it has been found that the cleaving of the soy proteins is sufficient to reduce the majority of whole soy proteins to peptides as determined by gel electrophoresis and peptide profile. Hydrolyzed soy isolate is available from Protein Technologies International (St. Louis, Mo.).

By way of example, and not limitation, embodiments of soy protein hydrolysate profiles are set forth below. Table 1 sets forth the soy protein hydrolysate specifications for an embodiment of the product.

Table 2 sets forth an embodiment of the amino acid profile of a preferred soy protein hydrolysate.

Table 3 sets forth the molecular weight distribution of a soy hydrolysate that has been found to function satisfactorily.

As noted, the above soy hydrolysate can be either the entire protein source or a protein thereof. The protein source can comprise, in an embodiment approximately 0.5% to about 5% by weight of a ready-to-use formula of the present invention. For a concentrate, this level, in an embodiment of the present invention, would be approximately 1.0 to about 10% by weight of the product.

In view of the soy hydrolysate, one of the issues with respect to the product is providing a stabilizer system. Pursuant to an embodiment of the present invention, neutral rice starch is utilized to stabilize the formula emulsion. Neutral rice starch provides stability as well as better hydration conditions and allows the product to be heat sterilized without degradation. In an embodiment, the stabilizer system is high amylose corn starch, kappa, or iota carragenan. However, it should be noted that a variety of stabilizer systems can be used. Such systems ideally should allow the product to be both aseptic and retort processable.

A number of stabilizer systems have been explored. By way of example, and not limitation, the physical stability of aseptic and retort processed soy hydrolysis-based infant formulas, based on the above soy hydrolysates, at the end of one month are set forth below in Table 4.

In addition to the protein source and stabilizer, the product will also include necessary macro and micronutrients to provide a complete nutritional product. In an embodiment of the present invention, a ready-to-use product will include approximately 1% to about 15% by weight carbohydrates. As a concentrate, in an embodiment of the present invention, the carbohydrates will comprise approximately 5% to about 20% by weight of the product.

In an embodiment of the present invention, the ready-to-use product will comprise approximately 1% to about 10% by weight fat. In an embodiment of the present invention as a concentrate, the product will comprise approximately 4 to about 20% by weight of fat.

The remaining components of the product will include vitamins and minerals with the majority of the product being water.

Set forth below are tables illustrating ready-to-feed formulas, concentrated infant formulas, and powdered infant formulas. Each of the tables sets forth embodiments of the formulations. In this regard, each of the tables sets forth, embodiments of possible ranges of each of the components.

The present invention provides improved infant formulas. These infant formulas can be utilized either as a supplement to or complete nutrition for the infant. Additionally, as illustrated above, the infant formulas can be provided as a ready-to-use product, a concentrate, or a powder that needs to be reconstituted. The formulas are designed to provide comfort to an infant. As used herein, a comfort formula is one that is more easily digestible for an infant or other individual. Due to the use of hydrolyzed soy, these formulas are easier for infants to digest.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

›Tables in the description — 6
TABLE 1 — Soy Protein Hydrolysate Specifications Per 100 grams
Protein Content65-90
Fat0.5-20
Moisture8 maximum
Calcium0.5-3.0
Phosphorus0.5-3.0
Sodium2 maximum
Potassium0.5-3.0
TABLE 2 — Amino Acid Profile of Soy Protein Hydrolysate g/100 g
Alanine4.20
Arginine7.70
Aspartic Acid11.30
Cysteine1.20
Glutamic Acid19.00
Glycine4.00
Histidine2.60
Isoleucine4.80
Leucine8.00
Lysine6.10
Methionine1.20
Phenylalanine5.30
Proline5.70
Serine5.20
Threonine3.70
Tryptophan1.40
Tyrosine3.70
Valine4.80
TABLE 3 — Molecular Weight Distribution
Molecular Weight Distribution% Peptides
Mol. Wt. In DaltonsAverageRange
>5000054-7
5000-500004844-51
1500-50002523-27
<5002219-25
Degree of Hydrolysis5.54.0-7.0
TABLE 5 — Ready-to-Feed Formula Dry matter basis % by weight
Preferable RangesPreferred Ranges
RAW MATERIALSUpperLowerUpperLower
RO water
Maltrin M-1807.6041.9016.1783.327
Soy hydrolysate isolate4.4360.8872.8831.553
Intact Soy IsolateUp to 50% of totalUp to 30% of total
proteinprotein
Sucrose2.3270.5821.8901.018
Palm Olein oil2.2260.5571.8090.974
Soybean oil1.2470.3121.0130.545
Coconut oil0.9800.2450.7960.429
Corn Starch0.8850.2210.7190.387
(High amylose)
H O Safflower Oil0.2760.0690.2250.121
Soy Lecithin 3 FUB0.2620.0660.2130.115
Dimodan BPT/K0.2180.0540.1770.095
Potassium Chloride0.1230.0310.1000.054
Sodium Citrate0.1110.0280.0910.049
Calcium Citrate, 4H2O0.0810.0200.0650.035
Sodium ascorbate0.0570.0140.0460.025
L-Methionine0.0390.0100.0310.017
Choline Bitartrate0.0280.0070.0230.012
Inositol0.0230.0060.0190.010
Magnesium Chloride0.0180.0040.0140.008
6H2O
Potassium Citrate0.01550.00390.01260.0068
Kappa-Carrageenan0.02030.00270.00880.0047
Taurine0.01050.00260.00850.0046
Alpha tocopherol acetate0.01010.00250.00820.0044
Iota-Carrageenan0.01350.00180.00590.0032
Ferrous sulfate0.00570.00140.00470.0025
Magnesium Oxide0.00510.00130.00410.0022
L-Carnitine0.00330.00080.00270.0015
Zinc sulfate0.00250.00060.00210.0011
Niacinamide0.00250.00060.00200.0011
Vitamin A acetate0.00180.00050.00150.0008
Vitamin K10.0015480.0003870.0012580.000677
Beta carotene0.0013710.0003430.0011140.000600
Vit D30.0009120.0002280.0007410.000399
Pantothenic acid0.0008440.0002110.0006860.000369
Potassium iodide0.0002830.0000710.0002300.000124
Copper sulfate0.0002430.0000610.0001980.000107
Riboflavin0.0001760.0000440.0001430.000077
Thiamine hydrochloride0.0001350.0000340.0001100.000059
Pyridoxine hydrochloride0.0001230.0000310.0001000.000054
Cobalamin0.0000610.0000150.0000490.000027
Folic Acid0.0000350.0000090.0000290.000015
Biotin0.0000130.0000030.0000110.000006
Sodium selenate0.0000060.0000010.0000050.000002
TABLE 6 — Concentrate Infant Formula Dry matter basis % by weight
Preferrable RangesPreferred Ranges
RAW MATERIALSUpperLowerUpperLower
RO water
Maltrin M-18014.8603.71512.0736.501
Soy hydrolysate isolate6.9311.7335.6323.032
Intact Soy IsolateUp to 50% of totalUp to 30% of total
proteinprotein
Sucrose4.5441.1363.6921.988
Palm Olein oil4.3481.0873.5331.902
Soybean oil2.4350.6091.9781.065
Coconut oil1.9130.4781.5540.837
Corn Starch1.7280.4321.4040.756
(High amylose)
H O Safflower Oil0.5400.1350.4390.236
Soy Lecithin, 3 FUB0.5120.1280.4160.224
Dimodan BPT/K0.4260.1060.3460.186
Potassium Chloride0.2400.0600.1950.105
Sodium Citrate0.2180.0540.1770.095
Calcium Citrate, 4H2O0.1570.0390.1280.069
Sodium ascorbate0.1110.0280.0900.049
L-Methionine0.0750.0190.0610.033
Choline Bitartrate0.0540.0140.0440.024
Inositol0.0450.0110.0370.020
Magnesium Chloride0.0340.0090.0280.015
6H2O
Potassium Citrate0.03020.00760.02460.0132
Kappa-Carrageenan0.03960.00530.01720.0092
Taurine0.02040.00510.01660.0089
Alpha tocophenol acetate0.01970.00490.01600.0086
Iota-Carrageenan0.02640.00350.01140.0062
Ferrous sulfate0.01120.00280.00910.0049
Magnesium Oxide0.00990.00250.00800.0043
L-Carnitine0.00650.00160.00530.0028
Zinc sulfate0.00500.00120.00400.0022
Niacinamide0.00490.00120.00400.0022
Vitamin A acetate0.00350.00090.00290.0015
Vitamin K10.0030240.0007560.0024570.001323
Beta carotene0.0026780.0006700.0021760.001172
Vit D30.0017820.0004460.0014480.000780
Pantothenic acid0.0016480.0004120.0013390.000721
Potassium iodide0.0005530.0001380.0004490.000242
Copper sulfate0.0004750.0001190.0003860.000208
Riboflavin0.0003430.0000860.0002790.000150
Thiamine hydrochloride0.0002640.0000660.0002140.000115
Pyridoxine hydrochloride0.0002400.0000600.0001950.000105
Cobalamin0.0001190.0000300.0000970.000052
Folic Acid0.0000690.0000170.0000560.000030
Biotin0.0000260.0000060.0000210.000011
Sodium selenate0.0000110.0000030.0000090.000005
TABLE 7 — Powder Infant Formula Dry matter basis % by weight
Preferable RangePreferred Range
RAW MATERIALSUpperLowerUpperLower
Maltnn M-18066.18816.54753.77828.957
Soy hydrolysate isolate27.2676.81722.15411.929
Intact Soy IsolateUp to 50% of totalUp to 30% of total
proteinprotein
Sucrose17.9944.49914.6207.872
Palm Olein Oil17.9784.49514.6077.866
Soybean oil10.0682.5178.1804.405
Coconut oil7.9101.9786.4273.461
H O Safflower Oil2.2320.5581.8130.976
Soy Lecithin, 3 FUB2.0280.5071.6470.887
Dimodan BPT/K0.0000.0000.0000.000
Potassium Chloride0.9500.2380.7720.416
Sodium Citrate0.8620.2150.7000.377
Calcium Citrate, 4H2O0.6260.1570.5090.274
Sodium ascorbate0.4400.1100.3580.193
L-Methionine0.2980.0740.2420.130
Choline Bitartrate0.2150.0540.1750.094
Inositol0.1800.0450.1460.079
Magnesium Chloride0.1370.0340.1110.060
6H2O
Potassium Citrate0.11970.02990.09720.0524
Taurine0.08080.02020.06570.0354
Alpha tocopherol acetate0.07800.01950.06340.0341
Ferrous sulfate0.04440.01110.03610.0194
Magnesium Oxide0.03920.00980.03180.0171
L-Camitine0.02570.00640.02080.0112
Zinc sulfate0.01970.00490.01600.0086
Niacinamide0.01950.00490.01580.0085
Vitamin A acetate0.01400.00350.01140.0061
Vitamin K10.0119750.0029940.0097300.005239
Beta carotene0.0106060.0026520.0086180.004640
Vit D30.0070570.0017640.0057340.003087
Pantothenic acid0.0065260.0016320.0053030.002855
Potassium iodide0.0021900.0005470.0017790.000958
Copper sulfate0.0018830.0004710.0015300.000824
Riboflavin0.0013600.0003400.0011050.000595
Thiamine hydrochloride0.0010440.0002610.0008480.000457
Pyridoxine hydrochlor-0.0009490.0002370.0007710.000415
ide
Cobalamin0.0004700.0001180.0003820.000206
Folic acid0.0002740.0000680.0002220.000120
Biotin0.0001030.0000260.0000830.000045
Sodium selenate0.0000430.0000110.0000350.000019

Claims as granted

28 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

6 codes
IPC · International Patent Classification
Section A — Human necessities
  • A23L33/00
  • A23L1/305
USPC · US Patent Classification
426/598426/801426/656426/661

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomJul 2001Jan 2002Jul 2002Jan 2003Jul 2003Jan 2004Jul 2004Jan 2005USPTOApplicantNon-final rejectionResponse after non-finalResponse after non-finalResponse after non-final
USPTOApplicanthover for detail · click to open
Pendency
3.4 y
1,237 days filing → grant
Office actions
3
non-final + final
Responses
3
no RCE
Examiner
Carolyn Paden
art unit 1761 · TC 1700
Citations: 30 back · 1 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom20022004200620082010201220142016201820202022Owner 1liens, releases & corrections
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock